Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PALI Palisade Bio	$0.68 +2.4%	$0.82	$0.60 ▼ $4.32	$6.05M	1.35	5.38 million shs	215,861 shs
PBM Psyence Biomedical	$2.97 -4.5%	$4.93	$2.36 ▼ $266.88	$5.81M	0.22	4.98 million shs	142,318 shs
SCNI Scinai Immunotherapeutics	$1.46 -1.4%	$1.94	$1.40 ▼ $6.18	$1.48M	1.86	354,048 shs	59,560 shs
TTNP Titan Pharmaceuticals	$3.99 -15.6%	$4.47	$3.03 ▼ $6.62	$6.29M	1.29	83,862 shs	76,480 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PALI Palisade Bio	-2.21%	-7.83%	-46.49%	-3.46%	-80.71%
PBM Psyence Biomedical	-2.51%	-5.76%	-66.01%	-40.42%	-98.82%
SCNI Scinai Immunotherapeutics	-3.90%	-3.90%	-27.80%	-44.98%	-63.46%
TTNP Titan Pharmaceuticals	-5.23%	-3.57%	+5.84%	+3.61%	-29.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
PALI Palisade Bio	2.7864 of 5 stars	3.5	4.0	3.3	0.0	0.6
PBM Psyence Biomedical	2.3298 of 5 stars	0.0	5.0	4.4	1.7	0.6
SCNI Scinai Immunotherapeutics	1.2663 of 5 stars	0.0	2.0	3.8	2.5	0.6
TTNP Titan Pharmaceuticals	0.4408 of 5 stars	0.0	3.0	3.5	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PALI Palisade Bio	3.00	Buy	$12.00	1,666.26% Upside
PBM Psyence Biomedical	0.00	N/A	N/A	N/A
SCNI Scinai Immunotherapeutics	0.00	N/A	N/A	N/A
TTNP Titan Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PALI Palisade Bio	$250K	24.78	N/A	N/A	$0.29 per share	2.34
PBM Psyence Biomedical	N/A	N/A	$1.71 per share	1.74	$11.83 per share	N/A
SCNI Scinai Immunotherapeutics	$660K	2.21	N/A	N/A	$5.10 per share	0.29
TTNP Titan Pharmaceuticals	$180K	29.48	N/A	N/A	$2.10 per share	1.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PALI Palisade Bio	-$14.44M	-$4.06	N/A	N/A	N/A	N/A	-214.94%	-135.09%	11/11/2025 (Estimated)
PBM Psyence Biomedical	$1.01M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SCNI Scinai Immunotherapeutics	$4.80M	-$9.57	N/A	∞	N/A	N/A	N/A	-40.60%	N/A
TTNP Titan Pharmaceuticals	-$4.71M	-$2.95	N/A	∞	N/A	N/A	-108.60%	-95.64%	N/A

Latest SCNI, PALI, TTNP, and PBM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	TTNP Titan Pharmaceuticals	N/A	-$0.65	N/A	-$0.65	N/A	N/A
8/11/2025	Q2 2025	PALI Palisade Bio	-$0.48	-$0.58	-$0.10	-$0.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
PALI Palisade Bio	N/A	N/A	N/A	N/A	N/A
PBM Psyence Biomedical	N/A	N/A	N/A	N/A	N/A
SCNI Scinai Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
TTNP Titan Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PALI Palisade Bio	N/A	1.62	1.62
PBM Psyence Biomedical	N/A	11.04	11.04
SCNI Scinai Immunotherapeutics	0.06	1.32	1.32
TTNP Titan Pharmaceuticals	N/A	11.60	11.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
PALI Palisade Bio	11.79%
PBM Psyence Biomedical	77.44%
SCNI Scinai Immunotherapeutics	58.41%
TTNP Titan Pharmaceuticals	31.49%

Insider Ownership

Company	Insider Ownership
PALI Palisade Bio	0.65%
PBM Psyence Biomedical	3.60%
SCNI Scinai Immunotherapeutics	60.90%
TTNP Titan Pharmaceuticals	0.72%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
PALI Palisade Bio	10	9.12 million	9.06 million	Not Optionable
PBM Psyence Biomedical	N/A	1.87 million	1.80 million	N/A
SCNI Scinai Immunotherapeutics	20	1.00 million	391,000	Not Optionable
TTNP Titan Pharmaceuticals	10	1.33 million	1.32 million	Optionable

SCNI, PALI, TTNP, and PBM Headlines

Recent News About These Companies

Titan Pharmaceuticals Approves Merger with Black Titan

August 26 at 11:40 PM | msn.com

TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP

August 5, 2025 | businesswire.com

URGENT: The M&A Class Action Firm Encourages $hareholders to Act Before Vote – Titan Pharmaceuticals, Inc. (Nasdaq: TTNP)

July 29, 2025 | globenewswire.com

Titan Pharmaceuticals Inc (TTNP) - Investing.com

July 4, 2025 | investing.com

Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock - Morningstar

June 29, 2025 | morningstar.comM

Titan Pharmaceuticals Completes Private Placement of Series C Convertible Preferred Stock with Blue Harbour Asset Management - Nasdaq

June 29, 2025 | nasdaq.com

Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock

June 27, 2025 | finance.yahoo.com

Titan Pharmaceuticals Completes Private Placement of Series C Convertible Preferred Stock with Blue Harbour Asset Management

June 27, 2025 | quiverquant.comQ

Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock

June 27, 2025 | globenewswire.com

titan pharmaceuticals issues common stock following preferred stock conversions

June 4, 2025 | investing.com

Titan announces filing of registration statement for proposed combination

June 4, 2025 | finance.yahoo.com

Titan Pharmaceuticals, Inc. Files Registration Statement for Proposed Merger with TalenTec Sdn. Bhd.

June 3, 2025 | quiverquant.comQ

Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.

June 3, 2025 | globenewswire.com

Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock

April 11, 2025 | globenewswire.com

Titan Pharmaceuticals: Q4 Earnings Snapshot

March 20, 2025 | sfgate.com

Titan Pharmaceuticals receives Nasdaq notice of non-compliance

November 27, 2024 | markets.businessinsider.com

Titan Pharmaceuticals Faces Nasdaq Compliance Challenges with Reporting and Audit Committee Requirements

November 27, 2024 | quiverquant.comQ

Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

November 27, 2024 | globenewswire.com

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat

October 25, 2024 | msn.com

Titan Pharmaceuticals, Inc. (TTNP)

October 17, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNI, PALI, TTNP, and PBM Company Descriptions

Palisade Bio NASDAQ:PALI

$0.68 +0.02 (+2.40%)

Closing price 04:00 PM Eastern

Extended Trading

$0.68 +0.00 (+0.38%)

As of 06:55 PM Eastern

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

Psyence Biomedical NASDAQ:PBM

$2.97 -0.14 (-4.50%)

Closing price 04:00 PM Eastern

Extended Trading

$3.00 +0.02 (+0.84%)

As of 07:53 PM Eastern

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

Scinai Immunotherapeutics NASDAQ:SCNI

$1.46 -0.02 (-1.35%)

Closing price 04:00 PM Eastern

Extended Trading

$1.46 +0.01 (+0.34%)

As of 07:27 PM Eastern

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Titan Pharmaceuticals NASDAQ:TTNP

$3.99 -0.74 (-15.64%)

Closing price 04:00 PM Eastern

Extended Trading

$3.98 -0.01 (-0.25%)

As of 07:38 PM Eastern

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time